Voriconazole-Associated Cutaneous Malignancy: A Literature Review on Photocarcinogenesis in Organ Transplant Recipients

Williams, Kristen; Mansh, Matthew; Chin‐Hong, Peter; Singer, Jonathan P.; Arron, Sarah T.

doi:10.1093/cid/cit940

Cited by 127 publications

(105 citation statements)

References 35 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…4,5,11,14,15,17 Voriconazole might increase the risk of skin cancer in organ transplant recipients, including HCT. 18 The risk of skin cancer for patients who had allogeneic HCT for non-malignant disease remains undefined. A report restricted to autologous HCT demonstrated a SIR of 2.55 for melanoma, and multivariate analysis revealed age ⩾ 45 years, male patients and relapse following HCT as risk factors for melanoma development.…”

Section: Methodsmentioning

confidence: 99%

Secondary solid cancer screening following hematopoietic cell transplantation

Inamoto¹,

Shah

Savani

et al. 2015

Bone Marrow Transplant

157

123

View full text Add to dashboard Cite

Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers, particularly beyond 5 years after HCT and without reaching a plateau overtime. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to facilitate implementation of cancer screening appropriate to HCT recipients. The working group reviewed guidelines and methods for cancer screening applicable to the general population and reviewed the incidence and risk factors for secondary cancers after HCT. A consensus approach was used to establish recommendations for individual secondary cancers. The most common sites include oral cavity, skin, breast and thyroid. Risks of cancers are increased after HCT compared with the general population in skin, thyroid, oral cavity, esophagus, liver, nervous system, bone and connective tissues. Myeloablative TBI, young age at HCT, chronic GVHD and prolonged immunosuppressive treatment beyond 24 months were well-documented risk factors for many types of secondary cancers. All HCT recipients should be advised of the risks of secondary cancers annually and encouraged to undergo recommended screening based on their predisposition. Here we propose guidelines to help clinicians in providing screening and preventive care for secondary cancers among HCT recipients.

show abstract

Section: Methodsmentioning

confidence: 99%

Secondary solid cancer screening following hematopoietic cell transplantation

Inamoto¹,

Shah

Savani

et al. 2015

Bone Marrow Transplant

157

123

View full text Add to dashboard Cite

show abstract

“…Another factor to consider with chronic suppressive therapy includes the increased risk of skin cancer associated with prolonged voriconazole exposure . For voriconazole, prolonged therapy should only be considered if the benefit outweighs the risk of developing skin cancer.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of chronic suppressive azole therapy for endemic fungal infections in solid organ transplant recipients

Trinh

Echenique

Penugonda

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Adverse effects reported with the systemic use of voriconazole include transient visual changes (20%), liver dysfunction (12%–20%) and photosensitivity reaction that causing sunburn-like erythema in sun-exposed area 8. Transient mild ocular discomfort is the only reported adverse effect with topical use of voriconazole in cases of mycotic keratitis 9…”

Section: Discussionmentioning

confidence: 99%

Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis

Sahay

Asif

Maharana³

et al. 2018

BMJ Case Reports

View full text Add to dashboard Cite

We present two cases of culture-proven fungal keratitis on natamycin treatment which developed periocular erythema, oedema, burning sensation and pruritus within 48 hours of the addition of topical voriconazole. On clinical examination, periocular erythema with induration was noted. A diagnosis of orbital cellulitis was suspected, but the absence of pain and tenderness refuted the diagnosis on clinical grounds. A dermatology consultation was sought, and a diagnosis of periocular contact dermatitis with voriconazole was made. A skin patch test was performed with the same medication; however, it was negative. Topical voriconazole therapy was withdrawn, and the patient was prescribed cold compresses and oral antihistamine medication, to which they responded well.

show abstract

Voriconazole-Associated Cutaneous Malignancy: A Literature Review on Photocarcinogenesis in Organ Transplant Recipients

Cited by 127 publications

References 35 publications

Secondary solid cancer screening following hematopoietic cell transplantation

Secondary solid cancer screening following hematopoietic cell transplantation

Safety and efficacy of chronic suppressive azole therapy for endemic fungal infections in solid organ transplant recipients

Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis

Contact Info

Product

Resources

About